Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Pfister

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Regulatory Toxicology and Pharmacology : RTP|May 26, 2016
Toxicokinetic and toxicodynamic considerations when deriving health-based exposure limits for pharmaceuticalsJohn F Reichard, M Andrew Maier, Bruce D Naumann, et al.
American Heart Journal|January 21, 2014
EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertensionOlivier Sitbon, Marion Delcroix, Emmanuel Bergot, et al.
Lancet (London, England)|March 11, 2008
Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa studyAlain C Tissot, Patrik Maurer, Juerg Nussberger, et al.
Regulatory Toxicology and Pharmacology : RTP|June 12, 2020
Deriving harmonised permitted daily exposures (PDEs) for paracetamol (acetaminophen) CAS #: 103-90-2Kamila Gromek, William Hawkins, Tanja Bernier, et al.
Regulatory Toxicology and Pharmacology : RTP|May 23, 2024
Comparison of permitted daily exposure (PDE) values for active pharmaceutical ingredients (APIs) - Evidence of a robust approachClaudia Sehner, Tanja Bernier, Kamila Blum, et al.
Immunity|April 23, 2005
CCL19 and CCL21 induce a potent proinflammatory differentiation program in licensed dendritic cellsBenjamin J Marsland, Patrick Bättig, Monika Bauer, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 26, 2016
Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort StudyMaurizio Cutolo, Ariane L Herrick, Oliver Distler, et al.
Cancer Chemotherapy and Pharmacology|February 14, 2013
A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomasSook Ryun Park, Giovanna Speranza, Richard Piekarz, et al.
Journal of Hypertension|December 5, 2006
A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicityPatrice M Ambühl, Alain C Tissot, Alma Fulurija, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|November 5, 2018
Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 studyAdaani Frost, Munir Janmohamed, Jason S Fritz, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Regulatory Toxicology and Pharmacology : RTP|May 26, 2016
Toxicokinetic and toxicodynamic considerations when deriving health-based exposure limits for pharmaceuticalsJohn F Reichard, M Andrew Maier, Bruce D Naumann, et al.
American Heart Journal|January 21, 2014
EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertensionOlivier Sitbon, Marion Delcroix, Emmanuel Bergot, et al.
Lancet (London, England)|March 11, 2008
Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa studyAlain C Tissot, Patrik Maurer, Juerg Nussberger, et al.
Regulatory Toxicology and Pharmacology : RTP|June 12, 2020
Deriving harmonised permitted daily exposures (PDEs) for paracetamol (acetaminophen) CAS #: 103-90-2Kamila Gromek, William Hawkins, Tanja Bernier, et al.
Regulatory Toxicology and Pharmacology : RTP|May 23, 2024
Comparison of permitted daily exposure (PDE) values for active pharmaceutical ingredients (APIs) - Evidence of a robust approachClaudia Sehner, Tanja Bernier, Kamila Blum, et al.
Immunity|April 23, 2005
CCL19 and CCL21 induce a potent proinflammatory differentiation program in licensed dendritic cellsBenjamin J Marsland, Patrick Bättig, Monika Bauer, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 26, 2016
Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort StudyMaurizio Cutolo, Ariane L Herrick, Oliver Distler, et al.
Cancer Chemotherapy and Pharmacology|February 14, 2013
A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomasSook Ryun Park, Giovanna Speranza, Richard Piekarz, et al.
Journal of Hypertension|December 5, 2006
A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicityPatrice M Ambühl, Alain C Tissot, Alma Fulurija, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|November 5, 2018
Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 studyAdaani Frost, Munir Janmohamed, Jason S Fritz, et al.
Pageof 4